Drugmakers are racing to shift weight-loss treatment from injections to tablets.
The change could expand access and push the market toward a projected $200bn value.
Novo Nordisk recently launched the first daily oral version of Wegovy in the US.
The pill mimics the same GLP-1 hormone targeted by popular injections.
Early prescription numbers suggest strong demand.
Patients cite convenience, lower cost and no need for refrigeration.
Rival Eli Lilly is preparing to release its own pill, orforglipron.
Competition between the two companies is intensifying as obesity rates climb globally.
Analysts expect broader insurance coverage to further increase uptake.
Injections still produce greater weight loss in trials.
However, pills may attract people unwilling to use needles.
Researchers believe oral treatments could improve affordability and reach new patients.
Health experts warn that side-effects and long-term costs remain concerns.
Even so, falling prices and new options signal a pivotal year for the obesity drug industry.
